Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir |
| Type de publication | Journal Article |
| Year of Publication | 2015 |
| Auteurs | Barrail-Tran A, Vincent C, Furlan V, Rosa I, Rosenthal E, Cheret A, Molina J-M, Taburet A-M, Piroth L, Grp ANRSHC30 QUADR |
| Journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY |
| Volume | 59 |
| Pagination | 7903-7905 |
| Date Published | DEC |
| Type of Article | Article |
| ISSN | 0066-4804 |
| Résumé | Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon-ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir. |
| DOI | 10.1128/AAC.01603-15 |